{"id":879952,"date":"2025-08-28T07:34:33","date_gmt":"2025-08-28T11:34:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/"},"modified":"2025-08-28T07:34:33","modified_gmt":"2025-08-28T11:34:33","slug":"trevi-therapeutics-to-participate-in-upcoming-september-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/","title":{"rendered":"Trevi Therapeutics to Participate in Upcoming September Conferences"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NEW HAVEN, Conn.<\/span>
\n <\/span>, Aug. 28, 2025<\/span><\/span> \/PRNewswire\/ — Trevi Therapeutics, Inc.<\/a>\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) \u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in September.<\/p>\n

\n

\n
\n \"Trevi
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n 2025 Wells Fargo Healthcare Conference
<\/u>
\n <\/b>
\n September 3<\/span> \u2013 5, 2025, Everett, Massachusetts<\/span>
Trevi Representatives:<\/b>\u00a0Jennifer Good, President and CEO, and Farrell Simon, Pharm.D. CCO<\/p>\n

\n
\n Cantor Global Healthcare Conference 2025
<\/u>
\n <\/b>
\n September 3<\/span> \u2013 5, 2025, New York, New York<\/span>
Trevi Representatives: <\/b>Jennifer Good<\/span>, President and CEO, and James Cassella<\/span>, Ph.D., CDO<\/p>\n

\n
\n Morgan Stanley 23rd<\/sup> Annual Global Healthcare Conference
<\/u>
\n <\/b>
\n September 8<\/span> \u2013 10, 2025, New York, New York<\/span>
Fireside Chat:<\/b>September 9<\/span>, 4:05 p.m. ET<\/span>
Trevi Representatives: <\/b>Jennifer Good<\/span>, President and CEO, and James Cassella<\/span>, Ph.D., CDO
Register here to watch the live presentation<\/a>.<\/p>\n

\n
\n H.C. Wainwright & Co. 27th<\/sup> Annual Global Investment Conference
<\/u>
\n <\/b>
\n September 8<\/span> \u2013 10, 2025, New York, New York<\/span>
Trevi Representatives: <\/b>Jennifer Good<\/span>, President and CEO, and Farrell Simon, Pharm.D. CCO<\/p>\n

\n
\n 2025\u00a0Leerink Partners Biopharma Summit
<\/u>
\n <\/b>
\n September 17<\/span> \u2013 19, 2025, Healdsburg, California<\/span>
Trevi Representative: <\/b>Jennifer Good<\/span>, President and CEO<\/p>\n

\n
\n European Respiratory Society (ERS) Congress
<\/u>
\n <\/b>
\n September 27<\/span> \u2013 October 1, 2025<\/span>, Amsterdam, Netherlands<\/span>
Trevi Representatives: <\/b>Jennifer Good<\/span>, President and CEO, and James Cassella<\/span>, Ph.D., CDO, Danine Summers<\/span>, Vice President of Medical Affairs, and Abbey Nakano<\/span>, Pharm.D., Associate Director of Medical Affairs<\/p>\n

\n About Trevi Therapeutics, Inc.<\/b>\u00a0\u00a0\u00a0\u00a0
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.<\/p>\n

Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients’ social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.<\/p>\n

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8\u2005weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.<\/p>\n

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.\u00a0<\/p>\n

For more information, visit\u00a0www.TreviTherapeutics.com<\/a>\u00a0and follow Trevi on\u00a0X<\/a>\u00a0(formerly Twitter) and\u00a0LinkedIn<\/a>.\u00a0<\/p>\n

\n Investor Contact<\/b>\u202f
Jonathan Carlson\u202f
Trevi Therapeutics, Inc.\u202f
(203) 654 3286\u202f
carlsonj@trevitherapeutics.com<\/a><\/u><\/p>\n

\n Media Contact<\/b>\u202f
Rosalia Scampoli\u202f
914-815-1465\u202f
rscampoli@marketcompr.com<\/a><\/u>\u00a0<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/trevi-therapeutics-to-participate-in-upcoming-september-conferences-302540243.html<\/a><\/p>\n

SOURCE Trevi Therapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW HAVEN, Conn. , Aug. 28, 2025 \/PRNewswire\/ — Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) \u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in September. 2025 Wells Fargo Healthcare Conference September 3 \u2013 5, 2025, Everett, MassachusettsTrevi Representatives:\u00a0Jennifer Good, President and CEO, and Farrell Simon, Pharm.D. CCO Cantor Global Healthcare Conference 2025 September 3 \u2013 5, 2025, New York, New YorkTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO Morgan Stanley 23rd Annual Global Healthcare Conference September … <\/p>\n

Continue reading “Trevi Therapeutics to Participate in Upcoming September Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-879952","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTrevi Therapeutics to Participate in Upcoming September Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevi Therapeutics to Participate in Upcoming September Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW HAVEN, Conn. , Aug. 28, 2025 \/PRNewswire\/ — Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) \u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in September. 2025 Wells Fargo Healthcare Conference September 3 \u2013 5, 2025, Everett, MassachusettsTrevi Representatives:\u00a0Jennifer Good, President and CEO, and Farrell Simon, Pharm.D. CCO Cantor Global Healthcare Conference 2025 September 3 \u2013 5, 2025, New York, New YorkTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO Morgan Stanley 23rd Annual Global Healthcare Conference September … Continue reading "Trevi Therapeutics to Participate in Upcoming September Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T11:34:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trevi Therapeutics to Participate in Upcoming September Conferences\",\"datePublished\":\"2025-08-28T11:34:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/\"},\"wordCount\":641,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/\",\"name\":\"Trevi Therapeutics to Participate in Upcoming September Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\",\"datePublished\":\"2025-08-28T11:34:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevi Therapeutics to Participate in Upcoming September Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevi Therapeutics to Participate in Upcoming September Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Trevi Therapeutics to Participate in Upcoming September Conferences - Market Newsdesk","og_description":"PR Newswire NEW HAVEN, Conn. , Aug. 28, 2025 \/PRNewswire\/ — Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) \u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in September. 2025 Wells Fargo Healthcare Conference September 3 \u2013 5, 2025, Everett, MassachusettsTrevi Representatives:\u00a0Jennifer Good, President and CEO, and Farrell Simon, Pharm.D. CCO Cantor Global Healthcare Conference 2025 September 3 \u2013 5, 2025, New York, New YorkTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO Morgan Stanley 23rd Annual Global Healthcare Conference September … Continue reading \"Trevi Therapeutics to Participate in Upcoming September Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-28T11:34:33+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trevi Therapeutics to Participate in Upcoming September Conferences","datePublished":"2025-08-28T11:34:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/"},"wordCount":641,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/","name":"Trevi Therapeutics to Participate in Upcoming September Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","datePublished":"2025-08-28T11:34:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-september-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trevi Therapeutics to Participate in Upcoming September Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/879952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=879952"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/879952\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=879952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=879952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=879952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}